In partnership with
The AI Weekly Brief
Your weekly brief of powerful AI tools, smart insights, and breakthrough trends - simplified for creators, freelancers, and entrepreneurs.
Issue 17 | March 2026 | Free Edition
Welcome back.
Imagine a computer so powerful it can complete a calculation in two hours that would take the world's fastest supercomputer over three years. Now imagine pointing that machine at one of humanity's most stubborn challenges: finding new medicines. That is no longer science fiction.
Market Volatility Exposes Weak Delegation
When markets get shaky, advisors don’t just manage portfolios. They manage fear, questions, follow-up and a flood of client communication.
That’s where weak delegation gets expensive.
If meeting prep, paperwork, CRM updates and account admin still run through you, response times slip and the client experience takes the hit.
BELAY created the free Financial Advisor’s Delegation Guide to help you identify what to hand off, what to keep and how to stay client-facing without losing control.
Inside, you’ll learn how to reduce bottlenecks, protect responsiveness and free up more time for the work only you should be doing.
In October 2025, Google's Quantum AI team published a landmark paper in Nature announcing something the field had been chasing for decades: the first verifiable quantum advantage on a scientifically meaningful problem. The chip at the center of it all is Willow, a 105-qubit processor that ran the Quantum Echoes algorithm 13,000 times faster than Frontier, currently the world's most powerful classical supercomputer. More importantly, the results could be independently confirmed, a first in quantum computing history.
What sets this moment apart from previous quantum milestones is not just speed. It is trust. Scientists can now verify the output on any comparable quantum machine and get the same answer. That reproducibility is the bridge between impressive physics demonstration and genuine scientific utility, and it opens a direct path into drug discovery.
What the Willow Chip Actually Did
The Quantum Echoes algorithm works similarly to sonar. A carefully crafted signal is sent into Google's quantum system, one qubit is perturbed, and then the signal is precisely reversed to listen for the returning echo. Because quantum waves amplify each other through a phenomenon called constructive interference, the measurement becomes extraordinarily sensitive to how information spreads across the chip.
In a proof-of-concept experiment conducted with the University of California, Berkeley, the team used Willow to analyze two small organic molecules: one containing 15 atoms and another with 28 atoms. The quantum results matched those from traditional Nuclear Magnetic Resonance spectroscopy (NMR), and then went further, revealing structural details that NMR alone could not detect.
Google's researchers describe this technique as a "molecular ruler", a tool capable of measuring distances between atoms with a precision that classical instruments simply cannot reach. For a full technical overview, Google's official Quantum AI blog lays out the full methodology and context.
Why Drug Discovery Needs This
Developing a new drug is brutally difficult. Classical computers can simulate the behavior of small molecules reasonably well, but the moment you scale up to the kind of complex protein interactions involved in most diseases, the computational cost becomes prohibitive. Quantum computers, by their nature, operate on the same physical principles as molecules themselves, making them fundamentally better suited to this kind of simulation.
The specific application being explored here is protein-ligand binding: understanding precisely how a candidate drug molecule attaches to its biological target. Get this wrong, and the drug either does not work or causes side effects. Get it right, and you dramatically compress the years-long journey from compound identification to clinical trial.
As pharmaphorum reported, quantum-enhanced NMR could become a central tool for determining how potential medicines bind to their targets, a task that today demands enormous time and resources from pharmaceutical research teams.
The Nobel Connection and What It Signals
The weight of this moment is underscored by who is behind it. Michel Devoret, Google Quantum AI's chief scientist of quantum hardware, is a co-author of the study and joint winner of the 2025 Nobel Prize in Physics for decades of foundational work in this area. His presence on the paper is not incidental. It signals that this result sits at the intersection of rigorous academic science and practical engineering.
"This marks a new step towards full-scale quantum computation," Devoret said at the announcement press briefing. Google CEO Sundar Pichai echoed that sentiment, describing the Quantum Echoes result as "a significant step toward the first real-world application of quantum computing." You can read Live Science's full coverage here.
Where Things Stand, Honestly
It is worth being clear-eyed here. Google's own vice president of engineering, Hartmut Neven, acknowledged that practical, real-world use of quantum computers in drug discovery is probably still several years away. The current system operates on a 65 to 105-qubit range. Fault-tolerant quantum computing at scale, the kind that would fully transform pharmaceutical pipelines, is expected to require logical qubits built from roughly 1,000 physical qubits each.
But the trajectory matters. In 2019, Google showed quantum computers could outperform classical ones on a contrived benchmark. In 2024, the Willow chip demonstrated that error correction actually improves as you add more qubits, solving a problem that had stumped researchers for nearly 30 years. Now in 2025, the system has achieved verifiable quantum advantage on a real scientific problem. Each step is narrower than the headlines suggest, and each step also genuinely builds on the last. For a measured technical assessment, the analysis at Applied Quantum is worth reading in full.
The Bigger Picture: AI and Quantum Working Together
What makes this moment particularly significant is not quantum computing alone. Google is actively combining its AI capabilities with its quantum hardware. TensorFlow Quantum, the company's open-source library for hybrid quantum-classical machine learning, allows AI models to work alongside quantum processors rather than being replaced by them. Machine learning is already being used to optimize qubit calibration and gate sequences, making the quantum hardware more reliable over time.
This hybrid approach, where quantum processors handle the parts of a problem that classical computers cannot, while AI orchestrates the workflow and interprets results, is likely how these systems will first reach pharmaceutical labs. The goal is not to replace existing drug discovery pipelines but to give researchers a tool that can see what was previously invisible at the atomic level.
Are you tracking agent views on your docs?
AI agents already outnumber human visitors to your docs — now you can track them.
What to Watch Next
Google has signaled that the 2026 to 2029 window is where early practical applications in drug discovery and materials science are most likely to emerge. Several major pharmaceutical companies are already in discussions with quantum computing providers under non-disclosure agreements, suggesting the industry is not waiting passively.
The path from a 28-atom molecule in a Berkeley lab to a life-saving medicine in a pharmacy is long. But for the first time, there is a credible, verifiable step in that direction built on quantum mechanics rather than classical approximations. That is genuinely new. And in a field where most promising technologies take decades to mature, a credible first step is worth paying close attention to.
Sources and Further Reading
Quantum Intelligence Weekly is an independent science and technology newsletter. No sponsored content. No paywalls.